X4 Pharmaceuticals to present WHIM Phase 3 clinical data at CIS meeting

X4 Pharmaceuticals announced that its submitted late-breaker abstract entitled "Results of a Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome" has been accepted for oral presentation at the Annual Meeting of the Clinical Immunology Society, which is taking place May 18-21, 2023, in St. Louis, MO. New data related to clinical secondary endpoints, among other assessments, are to be presented. In addition, X4 announced that the company will host a virtual event to present and discuss new data from the 4WHIM Phase 3 clinical trial at 4:00 pm ET on Tuesday, May 16, following expected publication of conference abstracts. In November 2022, X4 announced that the 4WHIM trial had met its primary endpoint and a key secondary endpoint, and that mavorixafor was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events. New data to be presented during the event will focus on additional secondary endpoints, including the impact of oral, once-daily mavorixafor on the rate, severity, and duration of infections, among other outcomes metrics, as measured during the 52-week trial period. Additionally, the company expects to provide an update on its U.S. regulatory activities in support of its potential New Drug Application-submission for mavorixafor for the treatment of WHIM syndrome, which is expected early in the second half of 2023.